Difference between revisions of "Team:Harvard BioDesign"
| Line 5: | Line 5: | ||
<h1><center>Welcome to the Harvard BioDesign's 2015 Team Wiki!</center></h1> | <h1><center>Welcome to the Harvard BioDesign's 2015 Team Wiki!</center></h1> | ||
| − | <p> | + | <p>Our team is engineering <i>E. Coli</i> to bind to colon cancer cells through the use of their type I pili, which are hair-like appendages |
| + | that have an adhesive domain. Naturally, the strains in <i>E. coli</i> that produce pili bind to alpha-D-mannose, which can cause urinary track infections. | ||
| + | However, our team is altering a non-harmful strain to produce pili using a modified Fim gene in order to localize the bacteria as a tool. For treatment of cancer, | ||
| + | once the bacteria are localized on the cells, the next step is to make the <E. coli</i> capable of producing a concentrated toxin or to administer a therapeutic. | ||
| + | Other potential applications for our <i>E. coli </i> include water pollution clean up through methods such as flocculation and targeting areas through GFP.</p> | ||
</body> | </body> | ||
Revision as of 03:59, 15 July 2015
Welcome to the Harvard BioDesign's 2015 Team Wiki!
Our team is engineering E. Coli to bind to colon cancer cells through the use of their type I pili, which are hair-like appendages
that have an adhesive domain. Naturally, the strains in E. coli that produce pili bind to alpha-D-mannose, which can cause urinary track infections.
However, our team is altering a non-harmful strain to produce pili using a modified Fim gene in order to localize the bacteria as a tool. For treatment of cancer,
once the bacteria are localized on the cells, the next step is to make the
